Curaleaf (CURA) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Meeting held virtually to enhance accessibility and shareholder engagement, with clear rules for participation and voting established at the outset.
Attendees were thanked for proxy submissions and informed about the use of technology for broader participation.
The agenda included presentation of financial statements, board elections, auditor appointment, and a Q&A session.
Corporate governance
Quorum was confirmed with at least two shareholders present by proxy, meeting requirements to proceed.
Proper notice of the meeting was confirmed, and official records were maintained as per legal requirements.
The number of directors was set at 10, with the board empowered to fill two vacancies until the next AGM.
Board and executive committee updates
Eight individuals were nominated and elected to the board, each qualifying under relevant corporate law.
No additional nominations were received, and all nominees confirmed willingness to serve.
Latest events from Curaleaf
- Q4 revenue hit $333M, margins improved, and international growth accelerated despite pricing pressure.CURA
Q4 202526 Feb 2026 - Q2 revenue up 2% to $342M, with 78% international growth and 48% adjusted gross margin.CURA
Q2 20242 Feb 2026 - Q3 saw stable revenue, margin gains, and 82% international growth amid U.S. market pressures.CURA
Q3 202416 Jan 2026 - Six directors elected, board set at 10, and auditor appointed with no shareholder questions.CURA
AGM 202513 Jan 2026 - 2024 revenue flat at $1.34B; international sales up 73% and margins improved.CURA
Q4 202423 Dec 2025 - International growth and product launches offset U.S. price pressure, driving Q2 results.CURA
Q2 202523 Nov 2025 - Q1 revenue fell 6% to $310M, but gross margin rose to 50% amid strong international growth.CURA
Q1 202517 Nov 2025 - Q3 revenue up 2% sequentially to $320M; international growth and margin gains offset price pressure.CURA
Q3 20256 Nov 2025